Nov 12
Healthcare holds up to 5 names from healthcare stocks above $200M. Selection follows the model's positive score together with its composite positive factor.
Equal capital goes into every recommendation. Recommendations are published a few hours before the open and placed as market orders, so buys and sells fill at the opening price. Positions are held for 6 to 21 days. Every position carries a 20% stop-loss: if the price touches it during the day, the position is sold there, at 80% of its entry price. Reported returns are measured from those opening prices and include every stop-loss exit.
Kahn Swick & Foti announced an investigation into Kyverna's officers and directors tied to a securities lawsuit alleging the 2024 IPO registration statement misstated or omitted adverse KYV-101 clinical data. Renewed litigation headlines can pressure sentiment and raise perceived governance risk in the near term.
Business WireAnalysts expect a Q3 2026 net loss of roughly $0.69 per share with negligible revenue. Investors will focus on confirmation that the rolling BLA submission for miv-cel in SPS remains on track for Q4 2026 completion and any FDA review commentary; a slip or cash burn surprise would be negative.
TickeronStoneX lifted its price target to $15 from $11 while keeping a Buy rating, citing shares having met the prior target. A higher PT from a credible firm can attract momentum buyers and reinforce the post-earnings bid.
Investing.comAt the Guggenheim Healthcare Innovation Conference, management cautioned investors not to "get over your skis" on the early 7% weight loss (only 8 subjects, 6 active) and noted the obesity franchise may need outside capital and partners. This tempered framing could cap upside enthusiasm ahead of the Q4 readout.
Investing.comBaird maintained an Outperform rating and $57 target (vs. ~$12.79 trading price), defending the PIK-201 dataset as validation of the PIKTOR program in endometrial and breast cancer. Analyst defense could support a near-term sentiment rebound given the wide gap to price targets ($40-$69 range).
Investing.comDespite meeting all Phase 1 endpoints, AbCellera will not advance ABCL575 past Phase 1, citing external developments in the OX40/OX40L class. The write-off of a pipeline asset is a modest negative, though focus shifting to ABCL635 limits the damage.
Fierce BiotechKyverna announced publication of the KYSA-8 registrational trial primary analysis in JAMA Neurology, showing statistically significant improvements across all primary and secondary endpoints at 16 weeks with a well-tolerated safety profile. Peer-reviewed validation of the lead asset ahead of the rolling BLA completion supports the regulatory narrative and could draw incremental institutional interest.
Kyverna Therapeutics Press ReleaseMBX confirmed the unblinded 12-week multiple ascending dose (Part C, Cohort 1) data for obesity candidate MBX 4291 remains on track for Q4 2026. This is the key near-term binary catalyst to confirm durability of the ~7% weight loss seen at 8 weeks and the tolerability profile; strong data could drive a sharp re-rating, weak data a selloff.
MBX Biosciences Press Release (GlobeNewswire)MBX will present preclinical pharmacokinetic data for MBX 6180, a once-monthly GLP-1/GIP/GCG triple agonist prodrug, at ObesityWeek 2026 (Nov 14-17, Washington D.C.). Positive preclinical exposure could reinforce the platform narrative and support sentiment into the event.
MBX Biosciences Press Release (GlobeNewswire)MBX reported Q3 2026 EPS of -$1.29 versus consensus -$0.80, with net loss widening to $62.4M (including $20.8M stock comp tied to former CEO award modification) and R&D up to $32.0M on Phase 3 start-up costs. Cash of $481.6M funds operations into 2029, limiting financing overhang, but the headline miss may weigh on near-term sentiment.
MBX Biosciences Press Release (GlobeNewswire)Faeth reported a 33% confirmed ORR (44% in PIK3CA-mutant patients), 83% DCR, and 7.4-month median PFS for PIKTOR plus paclitaxel in advanced endometrial cancer, with a manageable safety profile. While framed as positive and supportive of Phase 3 advancement, the market reacted negatively, suggesting investors viewed the efficacy bar as insufficient versus expectations.
Faeth Therapeutics Press ReleaseFTH fell more than 40% following the data release as investors questioned the 33% ORR and the exclusion of six patients from the efficacy-evaluable population. The sharp drawdown reflects heightened near-term volatility and negative sentiment that could persist or reverse on analyst defense.
Investor's Business DailyManagement disclosed a Type B FDA end-of-phase 2 meeting held November 3, 2026, with minutes still awaited and explicit regulatory guidance on a pivotal Phase 3 plan expected in H1 2027. The pending clarity on registrational path is a forward catalyst, though timing extends beyond the immediate two-week window.
StockAnalysis.com (Earnings Transcript)Oculis will host an in-person and virtual R&D Day on December 8, 2026, featuring comprehensive updates on the late-stage pipeline (Licaminlimab in DED, Privosegtor across neuro-ophthalmology/neurology) and insights from key opinion leaders. Such events can move shares via new data disclosures or reinforced guidance ahead of the PREDICT-1 readout.
Oculis Press Release (GlobeNewswire)Oculis management discussed its precision-medicine strategy, noting a CHF 100 million BlackRock debt facility and runway through 2H 2029 covering PREDICT-1 and PIONEER-1/2/3 trials. Reinforces funding security but is largely a reiteration of known financial position.
Investing.comAbCellera reported Q3 2026 EPS of -$0.13 vs. -$0.17 consensus and revenue of $10.63M vs. $6.21M expected, a wide top-line beat. The narrower loss and revenue surprise support near-term positive sentiment and validate the collaboration revenue base.
Investing.comABCL635 showed significant reductions in frequency/severity of vasomotor symptoms with favorable tolerability, and AbCellera plans late-stage development in 2027 plus expansion into cancer-treatment-induced VMS. The lead-program validation is the core driver of the recent share rally and near-term momentum.
Company Press ReleaseAbCellera completed a $200M equity offering, lifting available liquidity to roughly $890-900M. While dilutive, the strengthened balance sheet funds late-stage ABCL635 development and reduces financing risk, a net near-term positive for a clinical-stage biotech.
Company Press ReleaseFollowing an ~8.6% post-earnings move, ABCL trades near the top of its 52-week range with InvestingPro data flagging it as overvalued versus fair value. Elevated valuation and concentration risk in ABCL635 could cap near-term upside or invite profit-taking.
Investing.comKyverna management will present at the Jefferies Global Healthcare Conference in London on November 19, 2026. Conference appearances offer a venue for BLA timeline updates and pipeline commentary that can move the stock, particularly given proximity to the Q3 report.
Kyverna Therapeutics Press ReleasePatient randomization is complete in the PREDICT-1 registrational symptoms trial of Licaminlimab for TNFR1-mediated dry eye disease, with topline results anticipated around year-end 2026. This is a binary, stock-moving readout for the company's lead precision-medicine asset; positive data could drive significant upside, while a miss would be sharply negative.
Oculis Press Release (GlobeNewswire)Following positive FDA feedback supporting the regulatory pathway, Oculis expects IND clearance in Q4 2026 to initiate trials of Privosegtor in acute multiple sclerosis relapses. A near-term regulatory green light would expand the "pipeline-in-a-product" narrative and could act as a positive catalyst.
Oculis Press Release (GlobeNewswire)Oculis reported Q3 2026 results with net loss widening to CHF 18.24 million from a year earlier, alongside cash of $252.0 million and runway into 2H 2029. The widened loss is a modest negative, though the strong cash position and funded trial coverage mitigate financing overhang; shares rose modestly after-hours.
Oculis Press Release (GlobeNewswire)Stifel lifted its price target to $84 from $70 (Buy), citing the upcoming Part C readout and framing 6-8% weight loss as competitive, with ~10% plus better tolerability potentially pushing shares above $80. The note anchors bullish expectations ahead of the data and may amplify the reaction to the readout.
Investing.comKyverna has submitted the CMC module of its rolling BLA for miv-cel in SPS and remains on track to complete submission in Q4 2026, with plans to seek priority review under RMAT. Confirmation of this timeline is the key near-term regulatory catalyst and underpins the potential 2027 launch thesis.
SEC Filing (EX-99.1)